India’s first indigenous mRNA vaccine for the Omicron variant, GEMCOVAC-OM, developed by Pune-based Gennova Biopharmaceuticals Ltd, was approved under emergency use guidelines by the Drug Controller General of India late Monday. This comes a year after the company got approval for GEMCOVAC-19, the country’s first m-RNA vaccine against COVID-19
The Hindu JUNE 20, 2023 / 09:25 PM IST
The mRNA-based vaccine, GEMCOVAC-OM, was developed by Gennova Biopharmaceuticals using the indigenous platform technology, and supported under the Mission COVID Suraksha, implemented by Biotechnology Industry Research Assistance Council (BIRAC).
TheEconomicTimes JUNE 20, 2023 / 02:05 PM IST
The vaccine, named GEMCOVAC®-OM, is intended for individuals aged 18 years and older as a booster dose. It can be safely administered to individuals who have already received two doses of either Covaxin or Covishield. The vaccine is administered intradermally using a needle-free device, and it remains stable at temperatures between 2-8 °C.
CNBCTV • JUNE 20, 2023, 09:28 PM IST
The vaccine is the first booster Covid-19 vaccine developed in India against the highly transmissible Omicron variant and has demonstrated robust immune responses in phase 3 clinical trials. It is stable at two to eight degrees Centigrade and has been developed using Gennova’s indigenous platform technology, supported under ‘Mission Covid Suraksha’.
HindustanTimes • JUNE 06, 2023, 10:11 PM IST
Pune-based Gennova Biopharmaceuticals Ltd on Tuesday said its mRNA COVID-19 booster vaccine against the Omicron variant, GEMCOVAC-OM, has received emergency use authorisation from the Drugs Controller General of India. The booster vaccine can be administered safely to individuals who have received two doses of either Covaxin or Covishield, the company said adding, it is stable at 2-8 C.
NDTV • JUNE 20, 2023, 07:55 PM IST
Pune-based Gennova BioPharmaceuticals, which developed the country’s first mRNA vaccine and has now obtained approval for a mix-and-match booster dose based on the Omicron strain of the Sars-CoV-2 virus, says it can make a new vaccine based on an emerging strain within 100-days, if need be. Speaking to the media, Sanjay Singh, CEO, Gennova said...Read more
BusinessStandard • JUNE 20, 2023, 08:26 PM IST
Pune-based Gennova Biopharmaceuticals had submitted data to the drug regulator this month, amid an increase in the number of Covid-19 cases. Gennova, a subsidiary of Pune-based drugmaker Emcure, has developed an Omicron-specific vaccine GEMCOVAC-OM which has been assessed for its safety and immunogenicity...read more
ET BUREAU APRIL 12, 2023 / 12:33 AM IST
Gennova Biopharmaceuticals, subsidiary of Pune-based drugmaker Emcure has submitted data for its mRNA-based Omicron specific Covid-19 booster shot for authorisation to the drug regulator, amid increase in the number of Covid-19 cases.
ET BUREAU MARCH 21, 2023 / 01:24 AM IST
India is likely to get an Omicron-specific booster shot soon. Gennova Biopharmaceuticals, subsidiary of Pune-based drug maker Emcure, will soon submit data of clinical trials conducted on its mRNA vaccine that will target the Omicron variant of Covid-19 that is driving the surge in many countries.
ET BUREAU • DECEMBER 06, 2022, 11:52 PM IST
Messenger RNA (mRNA) technology has been central to the global response to Covid-19, enabling rapid manufacture of effective vaccines. But the virus continues to evolve, learning to out-maneuver prior immunity, whether from infection or from vaccination. To keep up, researchers and manufacturers alike have been developing the next generation of mRNA vaccines. Here, we take a look at one such example: India’s first home-grown mRNA vaccine, Gemcovac-19, manufactured by Gennova Biopharmaceuticals. The Office of the Drugs Controller General of India (DCGI) has granted the vaccine emergency use authorization (EUA), and an Omicron-specific booster shot is already in the works.
FORBES • OCTOBER 14, 2022, 10:52 AM EDT
The government is expected to start price negotiations with Pune-based Gennova Biopharmaceuticals, the makers of the country's first mRNA vaccine for the inclusion of the vaccine in the Covid-19 vaccination drive.
ET BUREAU • AUGUST 20, 2022, 06:58 AM IST
Gennova Biopharmaceuticals, a Pune-based company that is making India's first mRNA vaccine, has submitted its final vaccine trial data to the Drugs Controller General of India (DCGI) for evaluation. Earlier, sources said the company also developed an Omicron-specific vaccine, which would be tested on humans for efficacy and immunogenicity soon.
SNEHA MORDANI • MARCH 12, 2022, 10:08 IST
Indian pharma companies are working towards variant-specific vaccines as the Omicron variant evades immunity generated through two vaccine doses, according to NK Arora, Chief of National Technical Advisory Group on Immunization (NTAGI). In an interaction with the BusinessLine , he said that Gennova Biopharmaceuticals’s mRNA vaccine specifically made for Omicron variant is in the final clinical-trial stage, besides two other Indian companies’ vaccines which are in initial laboratory stage.
MONIKA YADAV • FEBRUARY 28, 2022, 03:01 AM IST
India has approved nine COVID-19 vaccines up until now, of which three - Serum Institute of India's Covishield, Bharat Biotech's Covaxin and Russian vaccine Sputnik V - are being administered in India to people who fit the eligibility criteria.
TIMESOFINDIA • FEBRUARY 18, 2022, 11:10 IST
PHASE 2/3 human trials of the country’s first homegrown mRNA vaccine developed by Pune-based Gennova Biopharmaceuticals have been completed and the firm is in the process of submitting data to the national regulatory authority. Plans are also afoot to test the vaccine in the pediatric population initially in a phase 2 trial.
ANURADHA MASCARENHAS • FEBRUARY 14, 2022, 07:35 IST
The Pune-based Gennova Biopharmaceuticals is expected to roll out India’s first home-grown mRNA (messenger ribonucleic acid) vaccine by April 2022. The COVID-19 pandemic awakened the world to the power of RNA therapies — two of the first vaccines that emerged in late 2020, Pfizer-BioNtech and Moderna, used this technology. Now, an Indian company is developing an mRNA vaccine from scratch, signaling possibilities of the use of the molecule in a variety of diseases beyond COVID-19.
JACOB KOSHY • FEBRUARY 13, 2022, 11:32 AM IST
India’s first homemade mRNA (messenger RNA) Covid vaccine is currently under the final stage of clinical trials, Covid-19 Task Force head and Niti Aayog member Dr. V K Paul said Thursday, February 10, 2021. Briefing the media, he said: “India’s first homegrown Messenger RNA Covid vaccine being developed by Pune-based Gennova Biopharmaceuticals is currently under final clinical trials, and we hope that we will be able to use it someday.”
THE INDIAN EXPRESS • FEBRUARY 10, 2022, 10:26 PM IST
“India’s first homegrown Messenger RNA (mRNA) COVID-19 vaccine being developed by Pune-based Gennova Biopharmaceuticals is currently under final clinical trials & we hope that we'll be able to use it someday,” Dr VK Paul said.
Hindustan Times • FEBRUARY 10, 2022, 08:11 PM IST